Hyperexpression of SCD1 is linked with a variety of metabolic disorders, like hypertriglyceridemia, and hence SCD1 inhibitors are attractive candidates to treat metabolic syndrome (Kamal et al., 2018). The gene discussed is SCD; the disease is metabolic disease.